NCT04578171View on ClinicalTrials.gov

Residual Exacerbations With Mepolizumab

RecruitingOBSERVATIONAL

Enrollment

60

Participants

Timeline

Start Date

July 6, 2021

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2028

Conditions

Asthma

Interventions

DRUG

Mepolizumab

100 mg subcutaneous injections every four weeks

Trial Locations (1)

G6K 1L8

RECRUITING

Institut universitaire de cardiologie et de pneumologie de Québec, Québec

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Laval University

OTHER

NCT04578171 - Residual Exacerbations With Mepolizumab | Biotech Hunter | Biotech Hunter